Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $40.4 million.

  • Gyre Therapeutics' Cash & Equivalents rose 154.10% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 154.10%. This contributed to the annual value of $11.8 million for FY2024, which is 64.75% down from last year.
  • Gyre Therapeutics' Cash & Equivalents amounted to $40.4 million in Q3 2025, which was up 10.69% from $36.5 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Cash & Equivalents high stood at $107.0 million for Q1 2021, and its period low was $6.9 million during Q3 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $15.9 million (2024), whereas its average is $20.9 million.
  • In the last 5 years, Gyre Therapeutics' Cash & Equivalents plummeted by 84.71% in 2023 and then surged by 154.10% in 2025.
  • Gyre Therapeutics' Cash & Equivalents (Quarterly) stood at $46.9 million in 2021, then crashed by 46.27% to $25.2 million in 2022, then skyrocketed by 33.10% to $33.5 million in 2023, then slumped by 64.75% to $11.8 million in 2024, then surged by 154.10% to $40.4 million in 2025.
  • Its last three reported values are $40.4 million in Q3 2025, $36.5 million for Q2 2025, and $15.0 million during Q1 2025.